The GidDy uP Kid
2 months ago
.1369...
NLSPโฆ
"AMENDMENT TO THE
NLS PHARMACEUTICS LTD.
COMMON STOCK PURCHASE WARRANTS
September 16, 2024
โThis Amendment No. 1, dated September 16, 2024 (the โEffective Dateโ), to each of the following four common stock purchase warrants (the โAmendmentโ), issued by NLS Pharmaceuticals Ltd, a Swiss corporation (the โCompanyโ), and each issued on or about (a) January 29, 2021, to Armistice Capital Master Fund Ltd. (โACMFโ or the โHolderโ or the โInvestorโ) to purchase 500,000 shares of the Companyโs common stock, par value CHF 0.02 (โCommon Stockโ), containing an exercise price of $4.15 per share (the โJanuary 2021 Warrantโ); (b) April 25, 2022, to ACMF to purchase 2,163,462 shares of Common Stock, containing an exercise price of $1.04 per share (the โApril 2022 Warrantโ); (c) March 22, 2024, to AMCF, to purchase 1,750,000 shares of Common Stock, containing an exercise price of $0.25 per share (the โMarch 2024 Warrantโ); and (d) July 1, 2024, to ACMF to purchase 2,500,000 shares of Common Stock, containing an exercise price of $0.24 per share (the โJune 2024 Warrantโ, and together with the January 2021 Warrant, April 2022 Warrant and March 2024 Warrant, the โExisting Warrantsโ, and each a โWarrantโ).โ
https://www.otcmarkets.com/filing/html?id=17845694&guid=G2L-kWrdbxRXB3h
On September 18, 2024, NLS Pharmaceutics Ltd., or the Registrant, convened an extraordinary shareholdersโ meeting, or the Meeting. At the Meeting, a quorum was present, and the shareholders of the Registrant approved all agenda items as originally proposed.
The Report on Form 6-K is incorporated by reference into the Registrantโs Registration Statements on Form F-3 (File No. 333-262489, and 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.โ"